

COMPLETION OF THE PROPOSED CAPITAL REDUCTION OF THE COMPANY

1. INTRODUCTION

- 1.1 The Board of Directors (the “**Board**” or the “**Directors**”) of Pharmesis International Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcements of the Company dated 3 March 2025 and 29 April 2025 (the “**Previous Announcements**”), and the Circular to Shareholders dated 7 April 2025 (the “**Circular**”) in relation to, inter alia, the Proposed Capital Reduction. Unless otherwise defined, capitalised terms herein shall have the same meaning as ascribed to them in the Circular.
- 1.2 As announced in the Company’s announcement dated 29 April 2025, the Capital Reduction Resolution was duly passed by the Shareholders in the Extraordinary General Meeting (“**EGM**”) held on the same day.

2. COMPLETION OF THE PROPOSED CAPITAL REDUCTION

- 2.1 Further to the Previous Announcements and the Circular, the Board is pleased to announce that the Company has complied with the requirements under Section 78C(1)(c) of the Companies Act and that no application for the cancellation of the Capital Reduction Resolution has been made by any creditor within the prescribed time-frame pursuant to the Companies Act.
- 2.2 The Company has accordingly lodged the relevant documents required under Sections 78E(2)(c) and (d) of the Companies Act with the Accounting and Corporate Regulatory Authority of Singapore on 23 June 2025.
- 2.3 The Proposed Capital Reduction is effective as of 23 June 2025. Accordingly, the Company’s issued and fully paid up share capital with effect therefrom is S\$11,754,089.53, comprising 31,700,000 ordinary shares.

By Order of the Board

Wu Xuedan
Executive Director and Chief Executive Officer

23 June 2025